No Data
Crispr Therapeutics Coverage Assumed by Guggenheim at Neutral
Guggenheim Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
Rigid Bull : That's what I'm doing :)